2-[3-(4-(methanesulfonyl-(methyl)-amino)-2-{[methoxycarbonyl-((S)-1-methyl-2-phenyl-ethyl)-amino]-methyl}-phenoxy)-phenyl]-propionic acid ethyl ester | 1198282-53-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-[3-(4-(methanesulfonyl-(methyl)-amino)-2-{[methoxycarbonyl-((S)-1-methyl-2-phenyl-ethyl)-amino]-methyl}-phenoxy)-phenyl]-propionic acid ethyl ester
• 英文别名: ethyl 2-[3-[2-[[methoxycarbonyl-[(2S)-1-phenylpropan-2-yl]amino]methyl]-4-[methyl(methylsulfonyl)amino]phenoxy]phenyl]propanoate
• CAS: 1198282-53-9
• 化学式: C₃₁H₃₈N₂O₇S
• 分子量: 582.718
• InChiKey: FRKXAGIRVSFLAP-NQCNTLBGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  41
• 可旋转键数：
  14
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  111
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
  申请人：Hutchinson John Howard

  公开号：US20110130453A1

  公开（公告）日：2011-06-02

  Described herein are compounds that are antagonists of PGD 2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD 2 receptors. Also described herein are methods of using such antagonists of PGD 2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD 2 -dependent or PGD 2 -mediated conditions or diseases.

  本文描述了一些PGD2受体拮抗剂化合物。还描述了包括这些化合物的制药组合物和药物，用于治疗呼吸系统、心血管系统和其他依赖或介导于PGD2的疾病或病症。同时，还描述了使用这些PGD2受体拮抗剂，单独或与其他化合物联合使用的方法。
• US8426449B2
  申请人：——

  公开号：US8426449B2

  公开（公告）日：2013-04-23
• [EN] AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS<br/>[FR] ANTAGONISTES D'AMINOALKYLPHÉNYLE DE RÉCEPTEURS DE PROSTAGLANDINE D2
  申请人：AMIRA PHARMACEUTICALS INC

  公开号：WO2009145989A2

  公开（公告）日：2009-12-03

  Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described herein are methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.